Kornimate/medical-research-clean huggingface dataset:
text message vaccine reminders for adolescents with chronic medical conditions

Conditions: Vaccination

Summary: there are a growing number of adolescents with chronic medical conditions in the united states. the advisory committee on immunization practices (acip) recommends hpv vaccination and annual influenza vaccination of all adolescents. pneumococcal polysaccharide vaccination is also recommended for certain high-risk patients. limited studies suggest that vaccination coverage of this population remains sub-optimal. text message vaccine reminder/recall has been shown to be effective in increasing uptake of select pediatric and adolescents vaccines, but has yet to be examined among patients with chronic medical conditions who may also face unique barriers to vaccination. this intervention aims to implement and evaluate the use of text message vaccine reminders among urban low-income minority adolescents with chronic medical conditions. this investigator-initiated study is supported in part by a grant from the pfizer medical education group.


Eligibility criteria:
inclusion criteria: parent with 1. adolescent aged 11-17 years; 2. adolescent with ≥1 chronic medical condition; 3. adolescent with clinic visit in last 12 months; 4. cell phone number listed in hospital registration system exclusion criteria: parent who: 1. does not speak english or spanish; 2. is unwilling to receive text message vaccine reminders; 3. anticipates moving from area in coming 12 months
moxifloxacin in situ gel to treat periodontal pocket.

Conditions: Chronic Generalized Periodontitis

Summary: in this randomized clinical trial locally delivered moxifloxacin in situ gel was evaluated as an adjunct to scaling and root planing for efficacy in the treatment of chronic periodontitis and for short-term effects on the periodontal microflora.

moxifloxacin exerts excellent antibacterial activity against a wide range of putative periodontal pathogens, including porphyromonas gingivalis, tannerella forsythia, prevotella species, fusobacterium nucleatum, actinomyces species, peptostreptococcus species, campylobacter rectus, and actinobacillus actinomycetemcomitans. moxifloxacin penetrates well into soft tissues and is effective against intracellular periodontal pathogens when used in the treatment of periodontitis as an adjunct to scaling and root planning (srp). systemic administration of moxifloxacin has provided superior outcomes compared with srp in conjunction with systemic administration of doxycycline, or srp alone. we hypothesized similar benefits with local drug delivery of moxifloxacin in the treatment of chronic periodontitis. to the best of our knowledge, there is no published literature on in situ gel using moxifloxacin employing gellan gum as the vehicle, for direct placement in the periodontal pocket for the treatment of chronic periodontitis. among various drug delivery systems for treating periodontitis, gel formulations have some advantages. despite a relatively faster release of the drug, gels can be more easily prepared and administered. moreover, they possess a higher bio compatibility and bio adhesivity, by allowing adhesion to the mucosa in the dental pocket and by decreasing the risk of dilution of the material by saliva. keeping the above facts in mind, the goals of this study were to (1) evaluate in situ gel as a vehicle in a local drug delivery system, (2) evaluate the efficacy of moxifloxacin for local drug delivery, (3) evaluate the efficacy of gellan gum for in situ gelation of moxifloxacin, and (4) evaluate and compare the clinical and microbiological parameters of moxifloxacin with those of the gold standard, chlorhexidine di gluconate.

Eligibility criteria:
inclusion criteria: * patients with good systemic health * patients with chronic periodontitis with sites with probing pocket depth (ppd) of ≥ 5 mm * a minimum of 12 natural teeth with radiographic evidence of bone loss * willingness to comply with the study protocol. exclusion criteria: * patients with a history of drug allergy to quinolones or those who were taking medication that might interact with moxifloxacin * patients with history of antibiotic coverage in the 6 months preceding the study * pregnant or lactating patients.

Keywords: moxifloxacin chlorhexidine in situ gel chronic periodontitis
comparative effect of vojta therapy and bobath therapy on lower limb spasticity and motorcity among hs

Conditions: Stroke

Summary: background: stroke is clinical defined as a neurological syndrome characterized by acute disruption of blood flow to an area of brain and corresponding onset of neurological defects related to the concerned area of brain. hemiplegic patient primarily affects the upper limb and lower limb of one side and typically results in flaccidity and difficulties with motor control and function.

the aim of this study will compare the effect of vojta therapy and bobath therapy on lower limb spasticity and motorcity among hemiparetic stroke patients. methodology: randomize clinical trials will be carried out on lower limb spasticity and motorcity among hemiparetic stroke patients. this study will include adult's stroke (1-4 months post- onset). inclusion criteria in which diagnosed with hemiplegic patients, aged 25-75 years and willingness to participants.

Eligibility criteria:
inclusion criteria: * diagnosed with hemiparetic stroke. * adult's stroke (1-4 months post- onset) * ability to follow instructions and participate in testing * aged 25-75 years. exclusion criteria: * previous history of brain surgery. * pregnant women. * limitation in cognitive skills like aphasia, deteriorated consciousness or dementia. * severe cardiovascular disease (unstable hypertension)"
green coffee extract and metabolic syndrome

Conditions: Metabolic Syndrome

Summary: metabolic syndrome (mets) is an assemblage of risk factors which can increase the risk of developing type 2 diabetes mellitus and cardiovascular disease. green coffee extract (gce) is derived from unroasted coffee beans and has substantial amounts of polyphenols primarily chlorogenic acids (cga). it has been shown that gce and cga can exert a positive influence over mets components including blood pressure, blood glucose, inflammation, oxidative stress, insulin resistance and blood lipids. up to our knowledge no study has been conducted on humans in the field of gca influences on mets patients. therefore, this study is planned to evaluate gca supplementation effects on anthropometric measurements, glycemic control, blood pressure, lipid profile in patients with metabolic syndrome.


Eligibility criteria:
inclusion criteria: * waist circumference\>102 cm in men and \>88 cm in women * fasting blood glucose\>100 mg/dl (5.6 mmol /l) * systolic blood pressure\>130 mmhg or diastolic blood pressure\>85mmhg * triglycerides\> 150 mg/dl (1.7 mmol/l) exclusion criteria: * insulin administration * pregnancy and breastfeeding * regular consumption of coffee and green tea
comparison of cuff-less wrist wearable blood pressure device to cuff based blood pressure measuring devices

Conditions: Hypertension; Healthy

Summary: (1) to compare cuff-less wrist wearable radial artery blood pressure measurements utilizing vitrack(developed by dynocardia) to the cuff based commercially available blood pressure device, in healthy volunteers with normal or high blood pressure.

(1) the vitrack is strapped over the radial artery at the wrist. the vitrack blood pressure cuff will be utilized to obtain blood pressure(bp) readings in the volunteers with normal or high blood pressure. the readings from the vitrack will be compared with the readings of a cuff-based, commercially available bp measuring device placed on the same arm.

Eligibility criteria:
inclusion criteria: * health volunteers 18 years and above; equal numbers of males and females to address sex as a biological variable (sabv); and in sinus rhythm. * agree to commit to participate in the current protocol. * provide written informed consent prior to any study procedures being performed (all subjects should be able to understand the informed consent form and any other documents that subjects are required to read). exclusion criteria: * unable or unwilling to provide informed consent * any other condition that would increase the risk of participation in the study in the opinion of the site investigator. * a difference of \>10 mm hg in left versus right arm oscillometric systolic bp. * upper extremity arteriovenous hemodialysis shunt. * wrist distortion or pain from arthritis. * prior trauma or surgery at the radial artery monitoring site.

Keywords: blood pressure, cuff less, wearable, bp
amoxicillin-clavulanate alone or in combination with ciprofloxacin in low-risk febrile neutropenic adult patients: a prospective, double-blind, randomized, non-inferiority multicenter, phase iii clinical trial.

Conditions: Febrile Neutropenia

Summary: in low risk neutropenic fever in cancer, standard of care is the association of amoxicillin clavulanate and ciprofloxacin. but in this population, the rate of fever related to infection is very low, leading to a overtreatment of the patients. the aim of this study is to validate a descalation of the antibiotherapy with safety concerns.


Eligibility criteria:
inclusion criteria: * patient ≥ 18 years old * treated for a solid cancer or a hematological malignancy * presented with low-risk\* febrile neutropenia due to chemotherapy with an expected duration of neutropenia ≤ 7 days * neutropenia is defined by an absolute neutrophil count ≤ 500/mm3. * fever is defined by temperature ≥ 38.3° or ≥ 38° twice during a 1-hour interval. * signing informed consent \*low risk is defined by mascc score ≥ 21 exclusion criteria: * hypersensitivity to the active substances: amoxicillin-clavulanic, ciprofloxacin, penicillins, to other quinolones or to one of the excipient * history of severe immediate hypersensitivity reaction to another beta-lactam * history of jaunditis/hepatic impairment related to amoxicillin/clavulanic * concomitant administration of ciprofloxacin and tizanidine. * clinical signs of focal infection including history of untreated dental abscess. * signs of sepsis or organ failure. * severe immune deficiency other than the current cancer, except controlled-hiv infection * gastrointestinal symptoms requiring intravenous treatment (mucositis, vomiting, severe diarrhea...). * known aminotransferase serum levels \> 5 x normal values. * known renal insufficiency defined as creatinine clearance of \< 30 ml/min (mdrd). * antibiotherapy within 24h before enrollment. prophylactic use of amoxicillin is an exclusion criterium whereas prophylactic use of trimethoprim-sulfamethoxazole (cotrimoxazole) and penicillin g (oracilline®) are not and will be considered in the analysis. * history of infection or colonization due to bacteria resistant to experimental drugs in the previous year * can be enrolled in the study only once. * patients not benefiting from a social security scheme or not benefiting from it through a third party. * persons benefiting from enhanced protection, namely minors, persons deprived of their liberty by a judicial or administrative decision, persons staying in a health or social institution, adults under legal protection, and finally patients in emergencies * pregnant or breastfeeding women, women at age to procreate and not using effective contraception (either hormonal / mechanical : oral, injection, subcutaneous, implantable, intrauterine device, or surgical : tubal ligation, hysterectomy, total ovariectomy).
the effect and safety of different doses of atropine on myopic progression of highly myopic children: multi-centered randomized clinical trial

Conditions: High Myopia

Summary: objective: to evaluate the efficacy of different concentrations of atropine eye drops in controlling the progression (diopter, axial length) of high myopia in young children, and to compare the compliance, adverse reaction and regression rate of different concentrations of atropine eye drops in myopia control. intervention: group 1 (0.01% atropine group), group 2 (0.04% atropine group), group 3 (0.1% atropine group). during the 2-year intervention period after entering the group, each concentration of atropine eye drops were given every night at a fixed time before going to bed, one drop each time, implemented by parents (supervision), and the wechat small program was completed.


Eligibility criteria:
inclusion criteria: * the bcva of distant vision is at least 0.5, near vision is at least 1.0, titmus stereo vision is less than 80 seconds, far exotropia is less than 10 prism degrees, far esotropia is less than 6-8 prism degrees, and astigmatism is equal to or less than - 2.50 d; * myopia progressed more than 0.5d in the past year; * have normal thinking and language communication skills, and be able to actively cooperate with the treatment as required; * written informed consent of guardian and child. exclusion criteria: * diseases of the study eye: keratitis, keratoconus, congenital cataract, glaucoma, fundus diseases; present situation with anterior segment or posterior segment inflammation, such as acute conjunctivitis, iridocyclitis; * systemic diseases affecting drug use: albinism, epilepsy, serious mental and neurological diseases, congenital heart disease, arrhythmia; * atropine allergy; * very low birth weight infants with birth weight less than 1500g; * receiving other treatment to control the development of myopia, including anticholinergic drugs such as atropine, or participated in other functional frame lens, multifocal soft lens in the past one year; * other situations that not suitable for participating in the trial as judged by the researcher
screening evaluation of the evolution of new heart failure (screen-hf)

Conditions: Heart Failure

Summary: the investigators are hoping to identify early heart failure in patients who do not have symptoms as yet and at the same time assess the usefulness of brain natriuretic peptide (bnp) in doing this.

measuring brain natriuretic peptide (bnp) and n-terminal probnp (nt-probnp)and can give us useful information about a persons heart function in patients with symptoms such as shortness of breath. this is because bnp/nt-probnp levels rise when the heart is under pressure as it is in people with heart disease. however, we don't know if this is a useful test to do in people who are at a high risk of developing heart disease but who have no symptoms and have not been diagnosed with any heart problems. in this study we hope to recruit 3500 participants. this study is being run in conjunction with hba (recently renamed bupa) and we estimate that 10,000 hba members will need to be contacted by letter and invited to screen for this study to achieve the required 3500 (protocol amended to include people who meet the entry criteria but who are not insured through hba). this protocol has been amended to allow us to invite 50 participants with the lowest nt-probnp levels to also continue in the study and have blood tests, an ecg and echocardiography as described below. participants will undergo a routine blood test which will include measuring nt-probnp. only participants in whom nt-probnp is elevated will undergo additional blood tests (for cardiac markers), an ecg and echocardiography to determine if there is any indication that they do have heart disease even though they have not been diagnosed and are not symptomatic.

Eligibility criteria:
inclusion criteria: 1. age ≥60 years 2. have been insured with hba for 12 months or longer (protocol amended to remove this criteria and allow enrollment of the general public) 3. subjects at high-risk of subsequent development of heart failure; comprising at least one of: * prior myocardial infarction (mi) without known left ventricular (lv) dysfunction * current active ischemic heart disease * prior cerebrovascular accident (cva) * known valvular heart disease without known lv dysfunction * atrial fibrillation * ventricular arrhythmia resulting in syncope or pre-syncope (protocol amended to remove this entry criteria) * treated hypertension, of at least 2 years duration * treated diabetes mellitus, of at least 2 years duration * estimated glomerular filtration rate (egfr) \<50ml/min exclusion criteria: 1. known systolic or diastolic heart failure 2. symptoms suggestive of current heart failure. (protocol amended to remove this criteria) 3. lv systolic or diastolic dysfunction on echocardiography or other objective imaging modality. 4. medications for treatment of heart failure such as ace inhibitors, angiotensin receptor blockers (arbs), beta-blockers or aldosterone antagonists. use of such medications for approved indications such as hypertension, post-mi management (without known lv dysfunction) or for diabetic nephropathy is permitted. (protocol amended to remove this criteria)

Keywords: heart failure bnp
continued evaluation of patients with parkinson's disease who previously received brt-da01

Conditions: Parkinson Disease

Summary: this is a multicenter study to evaluate the safety and clinical outcomes of brt-da01 in subjects with pd who previously received brt-da01 in the phase 1 study msk-da01-101.no investigational therapy will be administered in this study.

all subjects who received brt-da01 transplantation in study msk-da01-101 (ie, parent study) will be asked to enroll in study brt-da01-501. subjects enrolled in this study are to be monitored for safety and clinical outcomes through 5 years post-brt-da01 transplantation. for individual participating subjects, the baseline visit for the brt-da01-501 study will be defined as the last observation recorded in the parent study.

Eligibility criteria:
inclusion criteria: * subject received brt-da01 in study msk-da01-101 (ie, parent study) and will have completed or discontinued the parent study * subject must be willing and able to provide written informed consent for the brt-da0-501 study in accordance with applicable regulations and guidelines and to comply with all study visits and procedures exclusion criteria: * no exclusion criteria

Keywords: parkinson disease parkinsonian disorders basal ganglia diseases brain diseases central nervous system diseases nervous system diseases movement disorders synucleinopathies neurodegenerative diseases
comparison of deep versus moderate neuromuscular blockade on intra-operative blood loss during spinal surgery

Conditions: Spine Fracture

Summary: reduction of intra-operative blood loss

spine surgery is usually performed using a posterior approach with the patient in the prone position, but on the other hand this position causes venous engorgement in the back and increases bleeding with the risk of interruption of surgery and increases the need for blood transfusion. the prone position also produces undesirable haemodynamic changes resulting from compression of large vessels and decreased venous return to the heart. deep neuromuscular blockade has been shown to improve surgical conditions compared with moderate neuromuscular blockade in various surgical procedures specially different laparoscopic procedures to optimize surgical field conditions. in spine surgery, although many other factors such as the body habitus of the patient and the surgical equipment are important, an improvement in surgical field conditions can be achieved through reducing muscle tension in the back, and also reducing intra-abdominal and thoracic pressure. this goal may be attainable by using deep neuromuscular blockade. better operating conditions offer the surgeon easier access to the surgical field with less damage. however, the effect of deep neuromuscular blockade on surgical bleeding in spinal surgery in the prone position has been yet under evaluation. the investigators hypothesise that deep, compared with moderate, neuromuscular blockade would cause less surgical bleeding in spinal surgery in the prone position. the investigators aim to evaluate the effects and superiority of deep neuromuscular blockade on surgical bleeding in patients undergoing posterior lumbar interbody fusion surgery in the prone position.

Eligibility criteria:
inclusion criteria: * age 18- 65 years. * american society of anesthesiologists physical status classification (asa) i - iii * patients scheduled for posterior lumbar interbody fusion (2-level or 3-level). exclusion criteria: * urgent or emergency case or re-operation. * history of pre-operative anticoagulant medication or an indication for peri-operative anticoagulant medication. * asa classification more than iii. * age less than 16 years. * reduced left and right ventricular function (ejection fraction \<40%). * previous respiratory disease or a diagnosed neuromuscular disorder. * pre-operative dysrhythmia. * allergy to neuromuscular blocking agents. * family history of malignant hyperthermia. * decreased renal function (serum creatinine level more than twice the normal range, urine output \<0.5 ml kg/h, glomerular filtration ratio \<60 ml/ h).

Keywords: spine surgery anesthesia blood loss
effectiveness of augmented reality and repetitive transcranial magnetic stimulation

Conditions: Stroke

Summary: this study is to investigate the combined effects of repetitive transcranial magnetic stimulation (rtms) and augmented reality (ar) intervention on cortical excitability, balance, gait, activity in individuals with stroke. forty participants will be recruited in this study. they will be allocated to four group: rtms and ar group (10), sham rtms and ar group (10), ar group (10), and conventional physiotherapy group (10).

participants will be randomized allocated to four groups: rtms and ar group, sham rtms and ar group, ar group ,and conventional physiotherapy group in current study. all participants underwent four weeks, 3 sessions per week, and 60 minutes per session training program. motor evoked potential (mep), time up go test (tug), berg balance scale (bbs), fugl-meyer assessment (fma), multi-directional reach test (mdrt),the postural assessment scale for stroke patients (pass), and taiwanese depression questionnaires (tdq) will be assessed before and after intervention in all participants.

Eligibility criteria:
inclusion criteria: 1. cognitive ability is sufficient to understand the nature of study (mini-mental state examination score was above 23). 2. participants suffer from unilateral hemiplegia caused by a first-ever stroke. 3. participants are stable in medical and psychological condition. exclusion criteria: 1. participants have other neurologic problems that can affect balance and walking ability. 2. participants take of drugs or have other medical condition that can affect balance and function. 3. participants have contraindications for rtms intervention such as pacemaker, cochlear implants, metal in the brain or skull, open wound of brain, or history of epilepsy.

Keywords: repetitive transcranial magnetic stimulation (rtms) augmented reality (ar) stroke
whole exome sequencing in finding causative variants in germline dna samples from patients with congestive heart failure receiving therapy for breast cancer

Conditions: Breast Carcinoma

Summary: this research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (dna) samples from patients with congestive heart failure receiving therapy for breast cancer. studying samples of germline dna in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in dna and identify biomarkers related to congestive heart failure.

primary objectives: i. to identify, using next generation sequencing, rare variants of large effect size that impact the risk of congestive heart failure (chf) in patients from the clinical trial ecog-5103 (e5103). outline: previously collected germline dna samples are analyzed via whole exome sequencing.

Eligibility criteria:
inclusion criteria: * european american patients with dna available * european american patients who developed chf and patients who did not develop chf following a full course of treatment with an anthracycline and bevacizumab * african american cases (based on a drop in left ventricular ejection fraction \[lvef\] \ 20 points) and african american controls